SCHEMBL711873

SCHEMBL711873

COc1ccc(CNCc2csc(Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)n2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 4/20 0.58
PKM P14618 5/20 0.55
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
EGFR P00533 1/20 0.49
KDR P35968 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
CCNT1 O60563 4/20 0.49
CDK9 P50750 4/20 0.49
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
PPARG P37231 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711048 0.82 KMT2A (0.56) ALOX12PKMALDH1A1KMT2AMEN1
SCHEMBL714319 0.77 LMNA (0.58) ALOX12ALDH1A1KMT2AMEN1EGFR
SCHEMBL713201 0.77 PKM (0.48) PKMALDH1A1KMT2AMEN1EGFR
SCHEMBL711140 0.77 RXFP1 (0.55) PKMALDH1A1KMT2AMEN1EGFR
SCHEMBL713191 0.75 SCN3A (0.65) PKMALDH1A1KMT2AMEN1EGFR
SCHEMBL710421 0.75 MEN1 (0.47) PKMALDH1A1KMT2AMEN1EGFR
SCHEMBL713846 0.75 SCN1A (0.56) PKMALDH1A1KMT2AMEN1EGFR
SCHEMBL713129 0.75 LMNA (0.60) ALOX12PKMALDH1A1KMT2AMEN1
SCHEMBL710350 0.74 PKM (0.54) PKMALDH1A1KMT2AMEN1EGFR
SCHEMBL713265 0.74 PKM (0.54) ALOX12PKMALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALOX12 1666/4885PKM 2666/4885ALDH1A1 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.